evidence table
Rhodiola Cognition Randomized Trial Evidence Table
Structured evidence table for Rhodiola Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Rhodiola Cognition Randomized Trial | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Rhodiola Cognition Randomized Trial | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Rhodiola Cognition Randomized Trial | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Rhodiola Cognition Randomized Trial | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Rhodiola Cognition Randomized Trial | Failure to meet the recommended 7-9 hours of restful sleep per night is known to increase the risk of several health conditions, reason why regular and adequate sleep should be seen as a priority instead of an unnecessary commodity easily traded as required by the commitments of our busy lives. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Rhodiola Cognition Randomized Trial | While both the quantity and the quality of sleep can be largely improved with relatively straightforward practices dictated by good sleep hygiene, emerging research suggests that dietary and supplementation protocols focused on certain foods, nutrients, and biochemical compounds with sleep-promoting properties can act as subsidiary sleep aids in complementing these behavioral changes. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Rhodiola Cognition Randomized Trial | The scope of this narrative review is to summarize the available evidence on the potential benefits of selected nutraceuticals in the context of circadian rhythm and sleep disturbances, namely melatonin, magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, apigenin, valerian root, L-theanine, glycine, ashwagandha, myoinositol, Rhodiola rosea, and phosphatidylserine. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Rhodiola Cognition Randomized Trial | Humans spend approximately one third of their life asleep but, as counterintuitive as it may sound, sleep is far from being a quiet state of inactivity. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
Source documents